Clinical Trials Browser

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06555263 2025-08-22

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06676917 2025-08-08

TUXEDO-5

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05840770 2025-05-26

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Phase 2 Withdrawn

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06522360 2025-04-24

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04485026 2025-04-17

Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04889066 2024-12-20

Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02347839 2024-12-10

NEGOTIATE

Phase 2 Withdrawn

Thoracic

Lung Neoplasms

NCT02428764 2024-12-10

Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma

Phase 2 Withdrawn

Thoracic

Lung Neoplasms

NCT03164694 2024-12-10

APPEAL

Phase 2 Withdrawn

Thoracic

Lung Neoplasms

NCT06227897 2024-12-10

AERESA

Phase 2 Withdrawn

Thoracic

Lung Neoplasms

NCT03623776 2024-12-06

NAJSCR

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06068153 2024-11-20

AMBER

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04987281 2024-10-23

Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05718297 2024-10-08

BOUNCE

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05757843 2024-09-19

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06024941 2024-09-19

Re-Induce 2

Phase 2 Withdrawn

Thoracic

Lung Neoplasms

NCT04944173 2024-09-03

SCION

Phase 2 Withdrawn

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT04931420 2024-07-31

Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

Phase 2 Withdrawn

GastrointestinalThoracic

Gastrointestinal Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT05364645 2024-07-09

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05567055 2024-06-17

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05572476 2024-06-05

LURBIMUNE

Phase 2 Withdrawn

Thoracic

Small Cell Lung Carcinoma

NCT05999357 2024-05-29

STRIDER

Phase 2 Withdrawn

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05411107 2024-05-17

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Phase 2 Withdrawn

Thoracic

Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

NCT06331585 2024-04-25

Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05338580 2024-04-15

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

Phase 2 Withdrawn

DermatologicGenitourinaryThoracic

First-line Non-small-cell Lung Cancer

NCT05815186 2024-03-29

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Phase 2 Withdrawn

Thoracic

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT04102436 2024-03-12

Non-Viral TCR Gene Therapy

Phase 2 Withdrawn

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Urogenital Neoplasms

NCT06052423 2024-03-04

ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT03190239 2024-02-28

XQonc-007

Phase 2 Withdrawn

Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

NCT05703555 2024-02-28

INTRUSION

Phase 2 Withdrawn

BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Stomach Neoplasms

NCT02531854 2023-12-19

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05948462 2023-12-13

NSCLC

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT04648189 2023-10-19

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

Phase 2 Withdrawn

Thoracic

Lung Neoplasms, Neoplastic Cells, Circulating

NCT05161533 2023-10-18

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Phase 2 Withdrawn

Thoracic

Lung Neoplasms

NCT04989283 2023-09-26

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05045404 2023-09-13

Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05935774 2023-08-25

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05400577 2023-07-17

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05411679 2023-06-12

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Phase 2 Withdrawn

GastrointestinalThoracic

Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04699968 2023-06-07

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

INDIGO

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

EPIC

Neo-Kan

BIB 01

EMPIRE

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

TUXEDO-5

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

NEGOTIATE

Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma

APPEAL

AERESA

NAJSCR

AMBER

Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study

BOUNCE

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Re-Induce 2

SCION

Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

LURBIMUNE

STRIDER

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Non-Viral TCR Gene Therapy

ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer

XQonc-007

INTRUSION

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

NSCLC

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC